Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Growth Prospects Ahead For Johnson & Johnson (JNJ)

In “Squawk on the Street” on CNBC, the co-anchor of the show Jim Cramer, comments on the Q2 earnings of Johnson & Johnson (NYSE:JNJ), which beats analysts expectations, and the performance of its CEO, Alex Gorsky.

Johnson & Johnson (JNJ)

Commenting on the performance of the company, Cramer said:

“More about Pharma sales, that pretty incredible, domestic sales up 36%, a 2 cents raise, I am sure that time people are going to say, listen that’s not enough. You want to bet against Gorsky? (CEO of Johnson & Johnson) or sellout Gorsky? Go ahead, knock yourself out, it’s a mistake, this company is going higher.”

On the fact that the Johnson & Johnson (NYSE:JNJ) stock is up 8% since Q1 and a lot of other stocks also being up by 8% since Q1, Cramer said:

“Look, it’s a good drug stock and I think that what happens is that people say: you know what?  That’s not good enough, and then three weeks from now, they say, wait a second, of all the drug companies reported, Johnson & Johnson had the fastest growth. Now it’s pretty amazing.  The only other one that really touches it, is Allergan, and obviously Allegan is in play.”

According to Cramer, Johnson & Johnson (NYSE:JNJ) is a good drug stock to bet on looking at its growth prospects and according to him Allergan, Inc. (NYSE:AGN) is another drug stock that is similar to Johnson & Johnson (NYSE:JNJ) in terms of faster growth going ahead.

Meanwhile, Johnson & Johnson (NYSE:JNJ) announced on July 15, 2014 that the growing sales of its Hepatitis C drug has boosted its revenue as well as earnings for the second Quarter. The company has also raised its full-year earnings guidance to $5.85 to $5.92 a share compared to its previous guidance of $5.80 to $5.90 a share.

As part the announcement of latest results, the company’s sales of $19.5 billion for the second quarter of 2014, showed an increase of 9.1% compared to the same period last year. Moreover, net earnings i.e. excluding special items, were $4.8 billion, showing an increase of 11.3% over the same period for 2013.


Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!